Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Jan. 3, 2013 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), announced today
that Larry Andrews, President and Chief Executive Officer, is
presenting at Biotech Showcase™ 2013, which is being held in San
Francisco at the Wyndham Parc 55 Hotel at Union Square. Mr. Andrews
will provide a corporate update on Monday, January 7, 2013 at 1:45 PM
PST in the Powell Room, followed immediately by Q&A breakout session in
the Balboa Room.
To learn more about Biotech Showcase™ 2013 please visit their website http://bit.ly/134duey
Cipher's presentation will be available on their website www.cipherpharma.com.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty
pharmaceutical company that commercializes novel formulations of
successful, currently marketed molecules. Cipher's strategy is to
in-license clearly differentiated products, advance them through the
clinical development and regulatory approval stages, and out-license to
international marketing partners. Cipher's first product is a
fenofibrate formulation marketed in the United States as Lipofen®.
Cipher's second product, an extended-release tramadol, is marketed in
the United States as ConZip® and in Canada as Durela®. Cipher's third
product, a novel formulation of the acne treatment isotretinoin, was
approved by the FDA in May and was launched in the United States in Q4
2012 as Absorica™. The product was also recently approved by Health
Canada and Cipher expects to launch it as Epuris™ in Canada in Q2 2013.
For more information, please visit www.cipherpharma.com.